KMT2A and acute myeloid leukemia: Issa et al. reported the results of the AUGMENT-101 trial, the first-in-human phase I trial of the menin inhibitor SNDX-5613 (revumenib) in patients with relapsed/refractory AML KMT2A-rearranged (46 patients) and NPM1-mut (14 patients) patients; these patients were heavily pretreated [118].